Single dose of MDMA causes extensive decrement of serotoninergic fibre density without blockage of the fast axonal transport in Dark Agouti rat brain and spinal cord

Neuropathology and Applied Neurobiology

Volumn 33, Issue 2, 2007, Pages 193-203

  Kovacs G G ^a,b   Ando R D ^c   Adori C ^c   Kirilly, E ^c   Benedek, A ^d   Palkovits, M ^c   Bagdy, G ^a,c  

^a NATIONAL INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Hungary)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d EGIS PHARMACEUTICALS LTD   (Hungary)

Author keywords

Axonal transport; Ecstasy; MDMA; Serotonin; Serotonin transporter; Spinal cord; Tryptophan hydroxylase

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMYLOID PRECURSOR PROTEIN; MESSENGER RNA; SEROTONIN; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN REGION; CONTROLLED STUDY; EVALUATION; FRONTAL CORTEX; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MORPHOLOGY; NERVE FIBER; NERVE FIBER TRANSECTION; NERVE FIBER TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAPHE NUCLEUS; RAT; RAT STRAIN; SEROTONINERGIC NERVE; SEROTONINERGIC SYSTEM; SPINAL CORD; UPREGULATION;

ANIMALS; AXONAL TRANSPORT; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE FIBERS; RATS; RATS, INBRED STRAINS; RNA, MESSENGER; SEROTONIN; SEROTONIN AGENTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRYPTOPHAN HYDROXYLASE;

EID: 33847694981     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2006.00790.x     Document Type: Article

References (39)

1. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 2003; 55: 463-508
2. Lyles J, Cadet JL. Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms. Brain Res Brain Res Rev 2003; 42: 155-68
3. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 1988; 8: 2788-803
4. Callahan BT, Cord BJ, Ricaurte GA. Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine. Synapse 2001; 40: 113-21
5. Wang X, Baumann MH, Xu H, Rothman RB. 3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse 2004; 53: 240-8
6. Skagerberg G, Bjorklund A. Topographic principles in the spinal projections of serotonergic and non-serotonergic brainstem neurons in the rat. Neuroscience 1985; 15: 445-80
7. Tork I. Anatomy of the serotonergic system. Ann N Y Acad Sci 1990; 600: 9-34;discussion 34-5
8. Ridet JL, Geffard M, Privat A. Light and electron microscopic studies of the effects of p-chloroamphetamine on the monoaminergic innervation of the rat spinal cord. J Comp Neurol 1994; 343: 281-96
9. Nencini P, Woolverton WL, Seiden LS. Enhancement of morphine-induced analgesia after repeated injections of methylenedioxymethamphetamine. Brain Res 1988; 457: 136-42
10. Malpass A, White JM, Irvine RJ, Somogyi AA, Bochner F. Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats. Pharmacol Biochem Behav 1999; 64: 29-34
11. Balogh B, Molnar E, Jakus R, Quate L, Olverman HJ, Kelly PA, Kantor S, Bagdy G. Effects of a single dose of 3,4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naive rats and rats previously exposed to MDMA. Psychopharmacology (Berl) 2004; 173: 296-309
12. Harsing LG Jr, Gigler G, Albert M, Szenasi G, Simo A, Moricz K, Varga A, Ling I, Bagdy E, Kiraly I, Solyom S, Juranyi Z. Neurotransmitter release in experimental stroke models: the role of glutamate-GABA interaction. Adv Exp Med Biol 2004; 541: 21-37
13. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. San Diego: Academic Press, 1986
14. Hansson SR, Mezey E, Hoffman BJ. Serotonin transporter messenger RNA expression in neural crest-derived structures and sensory pathways of the developing rat embryo. Neuroscience 1999; 89: 243-65
15. Kirilly E, Benko A, Ferrington L, Ando RD, Kelly PA, Bagdy G. Acute and long-term effects of a single dose of MDMA on aggression in Dark Agouti rats. Int J Neuropsychopharmacol 2006; 9: 63-76
16. Ádori C, Andó RD, Kovács GG, Bagdy G. Damage of serotonergic axons and immunolocalization of Hsp27, Hsp72, and Hsp90 molecular chaperones after a single dose of MDMA administration in Dark Agouti rat: temporal, spatial, and cellular patterns. J Comp Neurol 2006; 497: 251-69
17. McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 2005; 30: 1741-50
18. Easton N, Marsden CA. Ecstasy: are animal data consistent between species and can they translate to humans? J Psychopharmacol 2006; 20: 194-210
19. O'Shea E, Granados R, Esteban B, Colado MI, Green AR. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 1998; 37: 919-26
20. Quate L, McBean DE, Ritchie IM, Olverman HJ, Kelly PA. Acute methylenedioxymethamphetamine administration: effects on local cerebral blood flow and glucose utilisation in the Dark Agouti rat. Psychopharmacology (Berl) 2004; 173: 287-95
21. Colado MI, Williams JL, Green AR. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 1995; 115: 1281-9
22. de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN, Segura J, Cami J. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 2000; 49: 104-9
23. Mockus SM, Vrana KE. Advances in the molecular characterization of tryptophan hydroxylase. J Mol Neurosci 1998; 10: 163-79
24. Weissmann D, Belin MF, Aguera M, Meunier C, Maitre M, Cash CD, Ehret M, Mandel P, Pujol JF. Immunohistochemistry of tryptophan hydroxylase in the rat brain. Neuroscience 1987; 23: 291-304
25. Joh TH, Shikimi T, Pickel VM, Reis DJ. Brain tryptophan hydroxylase: purification of, production of antibodies to, and cellular and ultrastructural localization in serotonergic neurons of rat midbrain. Proc Natl Acad Sci USA 1975; 72: 3575-9
26. Schmidt CJ, Taylor VL. Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 1987; 36: 4095-102
27. Lesch KP. Molecular biology, pharmacology, and genetics of the serotonin transporter: psychobiological and clinical implications. In Serotonergic Neurons and 5-HT Receptors in the CNS. Eds HG Baumgarten, M Göthert. Berlin, Heidelberg: Springer-Verlag, 2000; 671-707
28. Yu A, Yang J, Pawlyk AC, Tejani-Butt SM. Acute depletion of serotonin down-regulates serotonin transporter mRNA in raphe neurons. Brain Res 1995; 688: 209-12
29. Wang X, Baumann MH, Xu H, Morales M, Rothman RB. (+/?)-3,4- Methylenedioxymethamphetamine administration to rats does not decrease levels of the serotonin transporter protein or alter its distribution between endosomes and the plasma membrane. J Pharmacol Exp Ther 2005; 314: 1002-12
30. Ricaurte GA, Yuan J, McCann UD. (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 2000; 42: 5-10
31. Guyenet PG, Koshiya N, Huangfu D, Baraban SC, Stornetta RL, Li YW. Role of medulla oblongata in generation of sympathetic and vagal outflows. Prog Brain Res 1996; 107: 127-44
32. Greer GR, Tolbert R. A method of conducting therapeutic sessions with MDMA. J Psychoactive Drugs 1998; 30: 371-9
33. Takahashi T, Berger AJ. Direct excitation of rat spinal motoneurones by serotonin. J Physiol 1990; 423: 63-76
34. Wang MY, Dun NJ. 5-Hydroxytryptamine responses in neonate rat motoneurones in vitro. J Physiol 1990; 430: 87-103
35. Cazalets JR, Sqalli-Houssaini Y, Clarac F. Activation of the central pattern generators for locomotion by serotonin and excitatory amino acids in neonatal rat. J Physiol 1992; 455: 187-204
36. Ootsuka Y, Nalivaiko E, Blessing WW. Spinal 5-HT2A receptors regulate cutaneous sympathetic vasomotor outflow in rabbits and rats; relevance for cutaneous vasoconstriction elicited by MDMA (3,4-methylenedioxymethamphetamine, 'Ecstasy') and its reversal by clozapine. Brain Res 2004; 1014: 34-44
37. Bagdy G, Calogero AE, Murphy DL, Szemeredi K. Serotonin agonists cause parallel activation of the sympathoadrenomedullary system and the hypothalamopituitary-adrenocortical axis in conscious rats. Endocrinology 1989; 125: 2664-9
38. Medana IM, Esiri MM. Axonal damage: a key predictor of outcome in human CNS diseases. Brain 2003; 126: 515-30
39. Garcia-Osta A, Del Rio J, Frechilla D. Increased CRE-binding activity and tryptophan hydroxylase mRNA expression induced by 3,4- methylenedioxymethamphetamine (MDMA, 'ecstasy') in the rat frontal cortex but not in the hippocampus. Brain Res Mol Brain Res 2004; 126: 181-7